Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
102 results about "Muscarinic receptor site" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
M2 receptor. The M2 muscarinic receptors are located in the heart, where they act to slow the heart rate down to normal sinus rhythm, by slowing the speed of depolarization. In humans under resting conditions vagal activity dominates over sympathetic activity.
Novel m3 muscarinic acetylcholine receptor antagonists
InactiveUS20070179180A1BiocideOrganic chemistryMuscarinic receptor siteMuscarinic acetylcholine receptor M1
Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
Owner:GLAXO GROUP LTD
M3 muscarinic acetylchoine receptor antagonists
Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
Owner:GLAXO GRP LTD
Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
ActiveUS20140113946A1Reduce actionEliminate side effectsBiocideSenses disorderSide effectMuscarinic receptor site
The present invention is directed to compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism. The compositions include a cholinergic agent, such as a muscarinic acetylcholine receptor M3 agonist, and an alpha agonist having an imidazoline group or a non-steroidal anti-inflammatory agent (NSAID) having COX-2 selectivity. It has been found that an alpha agonist having an imidazoline group or non-steroidal anti-inflammatory agent (NSAID) having COX-2 selectivity in combination with a cholinergic agent, such as pilocarpine, act synergistically to improve the accommodative and focusing ability of the eye while minimizing the side effects from each compound.
Owner:ALLERGAN INC
Muscarinic acetylcholine receptor antagonists
Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Owner:GLAXO GROUP LTD
M3muscarinic acetylcholine receptor antagonists
M3 Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Owner:GLAXO GROUP LTD
Muscarinic acetylcholine receptor antagonists
Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Owner:GLAXO GRP LTD
M3 muscarinic acetylcholine receptor antagonists
Novel thiazole aniline compounds, pharmaceutical compositions, methods of making them and uses thereof in treating M3 muscarinic acetylcholine receptor mediated diseases are disclosed.
Owner:GLAXO GRP LTD
Muscarinic acetylcholine receptor antagonists
InactiveUS20060178395A1BiocideOrganic chemistryMuscarinic receptor siteMuscarinic acetylcholine receptor M4
Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Owner:GLAXO GROUP LTD
Muscarinic acetylcholine receptor antagonists
Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Owner:GLAXO GRP LTD
Muscarinic acetylcholine receptor antagonists
Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Owner:GLAXO GROUP LTD
Muscarinic acetylchoine receptor antagonists
Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
Owner:GLAXO GROUP LTD
Novel m3 muscarinic acetylcholine receptor antagonists
Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
Owner:GLAXO GROUP LTD
M3 muscarinic acetylchoine receptor antagonists
Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
Owner:GLAXO GROUP LTD
Muscarinic acetylcholine receptor antagonists
Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Owner:GLAXO GROUP LTD
Muscarnic acetylchorine receptor antagonists
Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Owner:GLAXO GROUP LTD
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
InactiveUS20050176664A1Improve bioavailabilityMinimize the possibilityCompounds screening/testingNervous disorderMuscarinic receptor siteCholinergic receptor muscarinic 3
This invention relates to compounds, compositions, and methods useful for modulating cholinergic muscarinic receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of cholinergic muscarinic receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of cholinergic muscarinic receptor genes, such as M3 muscarinic acetylcholine receptor or cholinergic receptor muscarinic 3 (CHRM3).
Owner:SIRNA THERAPEUTICS INC
Muscarinic Acetylcholine Receptor Antagonists
Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Owner:GLAXO GROUP LTD
Muscarinic acetylcholine receptor antagonists
InactiveUS20070173646A1BiocideOrganic chemistryMuscarinic receptor siteMuscarinic acetylcholine receptor M1
Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Owner:GLAXO GROUP LTD
M3 muscarinic acetylcholine receptor antagonists
Novel thiazole aniline compounds, pharmaceutical compositions, methods of making them and uses thereof in treating M3 muscarinic acetylcholine receptor mediated diseases are disclosed.
Owner:GLAXO GROUP LTD
RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
InactiveUS20050014172A1Improve bioavailabilityMinimize the possibilityCompounds screening/testingNervous disorderMuscarinic cholinergicFhit gene
The present invention relates to compounds, compositions, and methods useful for modulating the expression of genes associated with respiratory and pulmonary disease, such as cholinergic muscarinic receptor genes, using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of cholinergic muscarinic receptor genes, or other genes involved in pathways of cholinergic muscarinic receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of M3 muscarinic acetylcholine receptor or cholinergic receptor muscarinic 3 (CHRM3).
Owner:SIRNA THERAPEUTICS INC
4-Azaindole Derivatives
4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.
Owner:EISIA R&D MANAGEMENT CO LTD
Muscarinic Acetylcholine Receptor Antagonists
Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Owner:GLAXO GRP LTD
Muscarinic acetylcholine receptor antagonists
Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
Owner:GLAXO GROUP LTD
Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
ActiveUS20140200211A1Eliminate side effectsEasy to useBiocideSenses disorderSide effectMuscarinic receptor site
The present invention is directed to compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism. The compositions include a cholinergic agent, such as a muscarinic acetylcholine receptor M3 agonist, and an alpha agonist having an imidazoline group or a non-steroidal anti-inflammatory agent (NSAID) having COX-2 selectivity. It has been found that an alpha agonist having an imidazoline group or non-steroidal anti-inflammatory agent (NSAID) having COX-2 selectivity in combination with a cholinergic agent, such as pilocarpine, act synergistically to improve the accommodative and focusing ability of the eye while minimizing the side effects from each compound.
Owner:ALLERGAN INC
Muscarinic Acetylcholine Receptor Antagonists
Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Owner:LAINE DRAMANE I +3
Muscarinic Acetycholine Receptor Antagonists
Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Owner:GLAXO GROUP LTD
Muscarinic Acetylcholine Receptor Antagonists
Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
Owner:GLAXO GROUP LTD
M3 Muscarinic Acetylcholine Receptor Antagonists
The present invention is directed to novel Muscarinic Acetylcholine receptor antagonists of Formula (I), pharmaceutical compositions and methods of using them. Compounds of Formula (I) are, inter alia,
wherein:
- R1 and R2 are, independently, selected from the group consisting of
- 3-thienyl, pyridyl, benzyl, pyrimidyl, thiazolyl, isothiazolyl and C3-7cycloalkyl.
Owner:GLAXO GROUP LTD
M3 Muscarinic Acetylcholine Receptor Antagonists
Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
Owner:GLAXO GROUP LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap